Key facts
- This page summarizes Robert A. Eckert's Form 4 filing for AMGEN INC (AMGN).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 19 May 2022, 21:52.
Robert A. Eckert - 17 May 2022 Form 4 Insider Report for AMGEN INC (AMGN)
- Reporting relationship
- Director
- Issuer ticker
- AMGN
- Reported as of
- 17 May 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 May 2022, 21:52:47 UTC
- Prior SEC filing
- 10 May 2022
- Next SEC filing
- 20 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert A. Eckert
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert A. Eckert filed Form 4 for AMGEN INC (AMGN) on 19 May 2022.
Change
- Previous filing in this sequence was filed on 10 May 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AMGN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +855
- Change %
- +6.3%
- Price
- $0.000000
- Shares after
- 14,461
- Date
- 17 May 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.
Footnote F2
These shares include 1,894 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.